...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Drugs of today: Medicamentos de actualidad >Methoxypolyethylene glycol-epoetin beta for the treatment of anemia associated with chronic kidney disease.
【24h】

Methoxypolyethylene glycol-epoetin beta for the treatment of anemia associated with chronic kidney disease.

机译：甲氧基聚乙二醇-表皮素β用于治疗与慢性肾脏疾病相关的贫血。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Therapy with erythropoiesis-stimulating agents (ESAs) is a well-established treatment for renal anemia. ESAs are highly effective at correcting the underlying anemia, restoring energy levels and increasing patient well-being and quality of life. Anemia correction has considerable secondary benefits in terms of morbidity and mortality reduction. However, because of the relatively short halflife of ESAs, they generally have to be administered one to three times weekly in most patients. In order to overcome this shortcoming, in recent years pharmacological research has tried to modify the molecular structure of recombinant human erythropoietin (rHuEpo) in order to improve pharmacokinetics and pharmacodynamics and to allow a reduction in the frequency of administration. Covalent addition of the water-soluble polyethylene glycol moiety has been successfully used to improve the pharmacokinetics of a number of proteins and reduce their immunogenicity. A modified version of rHuEPO incorporating this large polymer chain, called continuous erythropoiesis receptor activator (CERA), has been recently synthesized. Data from animal studies indicate that CERA has a prolonged half-life in comparison with rHuEPO that may allow less frequent administration. Results of phase II and III clinical trials suggest that this agent is effective in maintaining hemoglobin levels after switching from rHuEPO therapy or darbepoetin alpha when administered charup to once a month. This less frequent administration schedule may be an advantage for patients and healthcare providers. In addition, this agent may give increased hemoglobin stability over time.
机译：促红细胞生成素（ESA）治疗是一种公认​​的肾性贫血治疗方法。 ESA在纠正潜在的贫血，恢复能量水平以及增加患者的健康和生活质量方面非常有效。贫血纠正在发病率和死亡率降低方面具有可观的次要益处。但是，由于ESA的半衰期相对较短，因此大多数患者通常每周必须对其进行1-3次给药。为了克服该缺点，近年来，药理学研究试图改变重组人促红细胞生成素（rHuEpo）的分子结构，以改善药代动力学和药效动力学并减少给药频率。水溶性聚乙二醇部分的共价添加已成功用于改善许多蛋白质的药代动力学并降低其免疫原性。最近已合成了结合了该大聚合物链的rHuEPO的改进版本，称为连续红细胞生成受体激活剂（CERA）。来自动物研究的数据表明，与rHuEPO相比，CERA的半衰期更长，这可能导致给药频率降低。 II期和III期临床试验的结果表明，当从药性转为每月一次时，从rHuEPO疗法或darbepoetinα切换后，该药物可有效维持血红蛋白水平。这种较不频繁的给药时间表对于患者和医疗保健提供者可能是一个优势。另外，该试剂可以随着时间的推移增加血红蛋白的稳定性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号